Therapeutic approaches to gastroesophageal junction adenocarcinomas

Annals of the New York Academy of Sciences

Volumn 1325, Issue 1, 2014, Pages 197-210

  Blom, Rachel L G M ^a   Bogush, Tatiana ^b   Brücher, Björn L D M ^c,d   Chang, Andrew C ^e   Davydov, Mikhail ^b   Dudko, Evgeny ^b   Leong, Trevor ^f   Polotsky, Boris ^b   Swanson, Paul E ^g   van Rossum, Peter S N ^h   Ruurda, Jelle P ^h   Sagaert, Xavier ⁱ   Tjulandin, Sergei ^b   Schraepen, Marie Celine ^j   Sosef, Meindert N ^j   van Hillegersberg, Richard ^h  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^c Box 980011   (United States)

^d Theodor Billroth Academy   (Germany)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ DEPARTMENT OF IMAGING AND PATHOLOGY   (Belgium)

^j Zuyderland Medical Centre   (Netherlands)

more..

Author keywords

Combined modality therapy; Gastroesophageal junction; OESO; PET CT; Tumor grading; Tumor markers; Tumor regression

Indexed keywords

CISPLATIN; TUMOR MARKER; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA; HUMAN; LOWER ESOPHAGUS SPHINCTER; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH ADENOCARCINOMA; SYSTEMATIC REVIEW (TOPIC); TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR REGRESSION; ADENOCARCINOMA; ANIMAL; ESOPHAGEAL NEOPLASMS; FRANCE; GENETICS; PATHOLOGY; STOMACH NEOPLASMS;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; PARIS; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84926126984     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12532     Document Type: Article

References (63)

1. Marsman, W.A., G.N. Tytgat, F.J. ten Kate & J.J. van Lanschot . 2005. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. J. Surg. Oncol. 92: 160-168.
2. Barbour, A.P., N.P. Rizk, M. Gonen, et al. 2007. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann. Surg. 246: 1-8.
3. Peyre, C.G., J.A. Hagen, S.R. DeMeester, et al. 2008. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann. Surg. 248: 549-556.
4. Peyre, C.G., J.A. Hagen, S.R. DeMeeste, et al. 2008. Predicting systemic disease in patients with esophageal cancer after esophagectomy: a multinational study on the significance of the number of involved lymph nodes. Ann. Surg. 248: 979-985.
5. Ronellenfitsch, U., M. Schwarzbach, R. Hofheinz, et al. 2013. Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst. Rev. 5: CD008107.
6. Apisarnthanarax, S. & J.E. Tepper . 2008. Crossroads in the combined-modality management of gastroesophageal junction carcinomas. Gastrointest. Cancer Res. 2: 235-243.
7. Cunningham, D., W.H. Allum, S.P. Stenning, et al. 2006. Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. N. Engl. J. Med. 355: 11-20.
8. van Hagen, P., M.C. Hulshof, J.J. van Lanschot, et al. 2012. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366: 2074-2084.
9. Sjoquist, K.M., B.H. Burmeister, B.M. Smithers, et al. 2011. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 12: 681-692.
10. Walsh, T.N., N. Noonan, D. Hollywood, et al. 1996. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 335: 462-467.
11. Tepper, J., M.J. Krasna, D. Niedzwiecki, et al. 2008. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J. Clin. Oncol. 26: 1086-1092.
12. Medical Research Council Oesophageal Cancer Working Group. 2002. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727-1733.
13. Stahl, M., M.K. Walz, M. Stuschke, et al. 2009. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J. Clin. Oncol. 27: 851-856.
14. Illig, R., E. Kleiser, T. Kiesslich & D. Neureiter . 2013. GERD-Barrett-adenocarcinoma: do we have suitable prognostic and predictive molecular markers? Gastroenterol. Res. Pract. [epub ahead of print] http://dx.doi.org/10.1155/2013/643084.
15. Dulak, A.M., P. Stojanov, S. Peng, et al. 2013. Exome and whole-genome sequencing of esophageal adenocarcinoma identified recurrent driver events and mutational complexity. Nat. Genet. 45: 478-486.
16. Agrawal, N., Y. Jiao, C. Bettegowda, et al. 2012. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2: 899-905.
17. Ayyappan, S., D. Prabhakar & S. Sharma . 2013. Epidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer. Anticancer Res. 33: 4139-4156.
18. Bang, Y.J., E. Van Cutsem, A. Feyereislova, et al. 2010. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376: 687-697.
19. Bettstetter, M., S. Berezowska, G. Keller, et al. 2013. Epidermal growth factor receptor, phosphatidylinositol-3-kinase catalytic subunit/PTEN and KRAS/NRS/BRAF in primary resection esophageal adenocarcinomas: loss of PTEN is associated with worse clinical outcome. Hum. Pathol. 44: 829-836.
20. Eto, K., M. Iwatsuki, M. Watanabe, et al. 2014. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to Trastuzumab. Ann. Surg. Oncol. 21: 343-350.
21. Farris, A.B., 3rd, E.G. Demicco, L.P. Le, et al. 2011. Clinicopathologic and molecular profiles of microsatellite unstable Barrett esophagus-associated adenocarcinoma. Am. J. Surg. Pathol. 35: 647-655.
22. Xie, L.X., T.T. Zhai, L.P. Yang, et al. 2013. Lymphangiogenesis and prognostic significance of vascular endothelial growth factor C in gastro-esophageal junction adenocarcinoma. Int. J. Exp. Pathol. 94: 39-46.
23. Mann, B., M. Madera, I. Klouckova, et al. 2010. A quantitative investigation of fucosylated serum glycoproteins with application to esophageal adenocarcinoma. Electrophoresis 31: 1833-1841.
24. Sarkaria, I.S., N.P. Rizk, M.S. Bains, et al. 2009. Post-treatment endoscopic biopsy is a poor-predictor of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann. Surg. 249: 764-767.
25. Schneider, P.M., R. Metzger, H. Schaefer, et al. 2008. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann. Surg. 248:902-908.
26. Swisher, S.G., M. Maish, J.J. Erasmus, et al. 2004. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann. Thorac. Surg. 78: 1152-1160; discussion 1152-60.
27. Griffin, J.M., C.E. Reed & C.E. Denlinger . 2012. Utility of restaging endoscopic ultrasound after neoadjuvant therapy for esophageal cancer. Ann. Thorac. Surg. 93: 1855-1859; discussion 1860.
28. Westerterp, M., H.L. van Westreenen, J.B. Reitsma, et al. 2005. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy-systematic review. Radiology 236: 841-851.
29. van Heijl, M., S.S. Phoa, M.I. van Berge Henegouwen, et al. 2011. Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer. Eur. J. Surg. Oncol. 37: 1064-1071.
30. Kwee, R.M. 2010. Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. Radiology 254: 707-717.
31. Lambrecht, M., V. Vandecaveye, F. De Keyzer, et al. 2012. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int. J. Radiat. Oncol. Biol. Phys. 82: 863-870.
32. van Rossum, P.S., R. van Hillegersberg, M. Lever, et al. 2013. Imaging strategies in the management of oesophageal cancer: what's the role of MRI? Eur Radiol. 23: 1753-1765.
33. Siewert, J.R., F. Lordick, K. Ott, et al. 2007. Induction chemotherapy in Barrett cancer - Influence on surgical risk ond outcome. Ann. Surg. 246: 624-631.
34. Chang, F., H. Deere, U. Mahadeva & S. George . 2008. Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy. Am. J. Clin. Pathol. 129: 252-262.
35. Mandard, A.M., F. Dalibard, J.C. Mandard, et al. 1994. Pathological assessment of tumor-regression after preoperative chemoradiotherapy of esophageal-carcinoma. Cancer 73, 2680-2686.
36. Langer, R., K. Ott, M. Feith, et al. 2009. Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Modern Pathol. 22: 1555-1563.
37. Swisher, S.G., W. Hofstetter, T.T. Wu, et al. 2005. Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann. Surg. 241: 810-820.
38. Chirieac, L.R., S.G. Swisher, J.A. Ajani, et al. 2005. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 103: 1347-1355.
39. Takebayashi, Y., S. Akiyama, S. Natsugoe, et al. 1998. The expression of multidrug resistance protein in human gastrointestinal tract carcinomas. Cancer 82: 661-666.
40. Aloia, T.A., D.H. Harpole, Jr., C.E. Reed, et al. 2001. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann. Thorac. Surg. 72: 859-866.
41. Langer, R., K. Ott, M. Feith, et al. 2010 High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. J. Surg. Oncol. 102: 503-508.
42. Gonzalez, V.M., M.A. Fuertes, C. Alonso & J.M. Perez . 2001. Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol. 59: 657-663.
43. Bogush, T.A., T.N. Zabotina, E.A. Bogush, et al. 2003. New approach to vital analysis of functional activity in ABC transporters (markers for multidrug resistance) in solid tumors by the method of flow cytofluorometry. Bull. Exp. Biol. Med. 135: 482-488.
44. Bogush, T.A., A.V. Konukhova, A.B. Ravcheeva, et al. 2003. Inhibition of ABC-transporter(s)' function in non-small cell lung cancer cells by platinum drugs. Antibiot. Khimioter. 48: 11-15.
45. Brücher, B.L.D.M., A. Bilchik, A. Nissan, et al. 2012. Tumor response criteria: are they appropriate ? Future Oncol. 8: 903-906.
46. Miller, A.B., B. Hoogstraten, M. Staquet & A. Winkler . 1981. Reporting results of cancer treatment. Cancer 47: 207-214.
47. Gurland, J. & R.O. Johnson . 1966. Case for using only maximum diameter in measuring tumors. Cancer Chemother. Rep. 50: 119-124.
48. Moertel, C.G. & J.A. Hanley . 1976. Hanley. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38: 388-394.
49. Breast Cancer Task Force Treatment Committee, 1977. National Cancer Institute: report from the combination chemotherapy trials working group. U.S. Department of Health, Education and Welfare. DHEW Publication No. (NIH) 77-1192.
50. Therasse, P., S.G. Arbuck, E.A. Eisenhauer, et al. 2000. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92: 205-216.
51. Brücher, B.L.D.M., H.J. Stein, M. Werner & J.R. Siewert . 2001. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer 92: 2228-2233.
52. Brücher, B.L.D.M., K. Becker, F. Lordick, et al. 2006. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106: 2119-2127.
53. Brücher, B.L.D.M., S. Swisher, A. Königsrainer, et al. 2009. Response to preoperative therapy in upper gastrointestinal cancers. Ann. Surg. Oncol. 16: 878-886.
54. Dikken, J., V. Lemmens, et al. 2012. Increased incidence and survival for oesophageal cancer but not for gastric cardia cancer in the Netherlands. Eur. J. Cancer 48: 1624-1632.
55. Smit, J., G. Sahin, et al. 2013. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients. Ann. Surg. Oncol. 20: 4008-4015.
56. Blom, R., W. Schreurs, et al. 2011. The value of post-neoadjuvant therapy PET-CT in the detection of interval metastases in esophageal carcinoma. Eur. J. Surg. Oncol. 37: 774-778.
57. Bruzzi, J., S. Swisher, et al. 2007. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. Cancer 109: 125-134.
58. Cerfolio, R., A. Bryant, et al. 2005. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvantchemoradiotherapy. J. Thorac. Cardiovasc. Surg. 129: 1232-1241.
59. van Heijl, M., J.M. Omloo, M.I. van Berge Henegouwen, et al. 2011. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann. Surg. 253: 56-63.
60. Vliegen, R. et al. Assessment of tumor response to neoadjuvante therapy in patients with esophageal cancer with use of diffusion-weighted MRI: initial experience. Unpublished data.
61. van Baardwijk, A., C. Dooms, et al. 2007. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1 alpha and GLUT-1 in non-small cell lung cancer. Eur. J. Cancer 43: 1392-1398.
62. 18F)HX4: a phase I trial. Eur. J. Nucl. Med. Mol. Imaging 37: 1663-1668.
63. Shapiro, J., F.J. ten Kate, P. van Hagen, K. Biermann, B.P. Wijnhoven & J.J. van Lanschot . 2013. Residual esophageal cancer after neoadjuvant chemoradiotherapy frequently involves the mucosa and submucosa. Ann. Surg. 258: 678-688.